|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101.70 USD | -0.15% |
|
-1.42% | -6.75% |
| 03:57pm | From Fed foresight to French fears |  |
| 12:25pm | Analyst recommendations: Merck, Salesforce, Block, Lyft, Bunzl... | |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions on site
| Capitalization | 258B 245B 228B 203B 362B 21,825B 398B 2,839B 1,052B 8,950B 968B 946B 38,522B | P/E ratio 2024 * |
14.3x | P/E ratio 2025 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise value | 280B 267B 248B 221B 394B 23,749B 433B 3,089B 1,145B 9,738B 1,053B 1,030B 41,917B | EV / Sales 2024 * |
4.38x | EV / Sales 2025 * | 3.96x |
| Free-Float |
70.72% | Yield 2024 * |
2.99% | Yield 2025 * | 3.14% |
More valuation ratios
* Estimated data
More news
Last Transcript: Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 week | -1.33% | ||
| Current month | +0.11% | ||
| 1 month | -0.12% | ||
| 3 months | -12.13% | ||
| 6 months | -20.95% | ||
| Current year | -6.67% |
1 week
100.46
103.04
1 month
94.48103.45
Current year
94.48134.63
1 year
94.48134.63
3 years
71.50134.63
5 years
65.25134.63
10 years
45.69134.63
| Director | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 2021-06-30 |
| Director of Finance/CFO | 55 | 2021-03-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 2020-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 64 | 2007-11-26 |
Patricia Russo
BRD | Director/Board Member | 71 | 1995-08-31 |
Robert Davis
CHM | Chairman | 57 | 2022-11-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 380 M€ | +9.14% | - | |
| 5.61% | 20 M€ | +16.48% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +0.01% | -1.33% | -3.15% | +38.59% | 258B | ||
| +3.79% | +6.24% | +42.98% | +239.95% | 732B | ||
| -0.29% | +4.92% | +12.68% | +120.15% | 488B | ||
| -0.86% | -2.90% | -5.03% | -7.40% | 367B | ||
| -1.39% | -2.51% | +23.82% | +47.09% | 321B | ||
| -0.45% | +0.36% | +2.88% | -31.06% | 231B | ||
| -3.26% | -2.95% | +4.49% | +20.61% | 210B | ||
| -2.90% | -0.53% | +2.05% | +25.27% | 212B | ||
| -0.30% | -1.28% | +1.44% | +32.42% | 150B | ||
| -0.92% | -2.13% | -13.66% | -50.89% | 145B | ||
| Average | -0.69% | +0.42% | +6.85% | +43.47% | 311.19B | |
| Weighted average by Cap. | +0.04% | +1.14% | +13.79% | +82.47% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 64.02B 60.9B 56.73B 50.56B 90.06B 5,423B 98.87B 705B 261B 2,224B 241B 235B 9,572B | 67.53B 64.24B 59.84B 53.34B 94.99B 5,720B 104B 744B 276B 2,346B 254B 248B 10,096B |
| Net income | 17.79B 16.92B 15.76B 14.05B 25.02B 1,507B 27.47B 196B 72.66B 618B 66.84B 65.34B 2,660B | 22.17B 21.09B 19.64B 17.51B 31.18B 1,878B 34.24B 244B 90.55B 770B 83.29B 81.43B 3,314B |
| Net Debt | 22.7B 21.6B 20.12B 17.93B 31.94B 1,923B 35.06B 250B 92.74B 789B 85.3B 83.39B 3,394B | 9.47B 9.01B 8.4B 7.48B 13.33B 803B 14.63B 104B 38.7B 329B 35.6B 34.8B 1,417B |
More financial data
* Estimated data
Employees
71,000
Sector
Pharmaceuticals
Calendar
2024-12-05
- Citi Global Healthcare Conference
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-04 | 101.64 $ | -0.21% | 3,963,123 |
| 24-12-03 | 101.85 $ | +1.23% | 11,395,586 |
| 24-12-02 | 100.61 $ | -1.01% | 13,703,135 |
| 24-11-29 | 101.64 $ | -1.44% | 6,081,177 |
| 24-11-27 | 103.12 $ | +1.48% | 9,802,172 |
Delayed Quote Nyse, December 04, 2024 at 11:01 am EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
101.85USD
Average target price
130.33USD
Spread / Average Target
+27.96%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MRK Stock